Effects of cilostazol on cognitive deficits in mice after repeated administration of phencyclidine

Clinical Psychopharmacology and Neuroscience

Volumn 8, Issue 1, 2010, Pages 26-29

  Hashimoto, Kenji ^a   Fujita, Yuko ^a   Ishima, Tamaki ^a   Horio, Mao ^a   Hagiwara, Hiroko ^a   Tanibuchi, Yuko ^a   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Cilostazol; Cognition; NMDA receptor; Phencyclidine; Schizophrenia

Indexed keywords

CARBOXYMETHYLCELLULOSE; CILOSTAZOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MALE; MENTAL TEST; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; RECOGNITION; REPEATED DRUG DOSE; SCHIZOPHRENIA;

EID: 77952020418     PISSN: 17381088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321-330.
2. Freedman R. Schizophrenia, N Engl J Med 2003;349:1738-1749.
3. Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 2004;174:32-38. (Pubitemid 38925088)
4. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56:301-307. (Pubitemid 39164514)
5. Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophrenia Res 2005;74:15-26.
6. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.
7. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
8. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia, Harv Rev Psychiatry 1996;3:241-253.
9. Krystal JH, D'Souza DC, Petrakis IL, Beiger A, Berman RM, Charney DS, et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999;7:125-143.
10. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003;60:572-576.
11. Hashimoto K, Okamura N, Shimizu E, Iyo M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr Med Chem CNS Agents 2004;4:147-154. (Pubitemid 38639374)
12. Hashimoto K, Shimizu E, Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev 2005;1:151-163.
13. Hashimoto K. The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin Psychopharmacol Neurosci 2006;4:3-10. (Pubitemid 44352184)
14. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 2004;29:300-307. (Pubitemid 38175148)
15. Hashimoto K, Fujita Y, Shimizu E, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol Eur J Pharmacol 2005;519:114-117. (Pubitemid 43181173)
16. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 2007;32:514-521. (Pubitemid 46271046)
17. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry 2008;63:92-97. (Pubitemid 350234890)
18. Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacology 2008;18:414-421. (Pubitemid 351608551)
19. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptor. Eur Neuropsychopharmacology 2008;18:448-454.
20. Ishima T, Fujita Y, Kohno M, Kunitachi S, Horio M, Takatsu Y, et al. Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J 2009;2:7-11.
21. Kimura Y. Selective type III phosphodiesterase inhibitor as an antithrombotic agent. Nippon Yakurigaku Zasshi 1995;106:205-216.
22. Schrör K. The pharmacology of cilostazol. Diabetes Obes Metab 2002;4(Suppl 2):S14-19.
23. Kumar M, Bhattacharya V. Cilostazol: a new drug in the treatment intermittent claudication. Recent Pat Cardiovasc Drug Discov 2007;2:181-185. (Pubitemid 350200286)
24. Hong KW, Lee JH, Kima KY, Park SY, Lee WS. Cilostazol: therapeutic potential against focal cerebral ischemic damage. Curr Pharm Des 2006;12:565-573.
25. Honda F, Imai H, Ishikawa M, Kubota C, Shimizu T, Fukunaga M, et al. Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. Stroke 2006;37:223-228.
26. . Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 2006;37:1539-1545. (Pubitemid 44305739)
27. Lee JH, Park SY, Shin YW, Hong KW, Kim CD, Sung SM, et al. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res 2006; 1082:182-191.
28. Wakida K, Morimoto N, Shimazawa M, Hozumi I, Nagase H, Inuzuka T, et al. Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and -2. Brain Res 2006;1116:187-193. (Pubitemid 44485011)
29. Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW. Poly (ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat. Brain Res 2007;1152:182-190.
30. Lee JH, Park SY, Shin YW, Kim CD, Lee WS, Hong KW. Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats. Brain Res 2007;1185:246-255.
31. Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW. Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury. CNS Neurosci Ther 2008;14:143-152.
32. Halene TB, Siegel SJ. PDE inhibitors in psychiatry - future options for dementia, depression and schizophrenia. Drug Discov Today 2007;12:870-878.
33. Siuciak JA. The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 2008;22:983-993.
34. Choi JM, Shin HK, Kim KY, Lee JH, Hong KW. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 2002;300:787-793.
35. Lee JH, Lee YK, Ishikawa M, Koga K, Fukunaga M, Miyakoda G, et al. Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats-an MRI study. Brain Res 2003;994:91-98.
36. Hashimoto K, Fujita Y, Horio M, Hagiwara H, Tanibuchi Y, Iyo M. Effects of cilostazol on dizocilpine-induced hyperlocotion and prepulse inhibition deficits in mice. Clin Psychopharmacol Neurosci 2010. In press.
37. Nishimura K, Ishigooka J, Imamura Y, Ihara S. Cilostazol, a cAMP phosphodiesterase 3 inhibitor, in the treatment of poststroke depression. J Neuropsychiatry Clin Neurosci 2007;19:471-472. (Pubitemid 350156109)
38. Baba H, Kubota Y, Suzuki T, Arai H. Seven cases of late-life depression treated with cilostazol-augmented therapy. J Clin Psychopharmacol 2007;27:727-728. (Pubitemid 351339473)
39. Takahashi K, Oshima A, Inoue K, Takeyoshi H, Fukuda M, Mikuni M. Novel augmentation therapy with cilostazol for the geriatric major depressive disorder patient with deep white matter hyperintensities on T2-weighted brain MRI: a case report. Pharmacopsychiatry 2008;41:37-39. (Pubitemid 351195891)